| ID | 1280 |
| Name of the vaccine | Tritanrix HB+Hib |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | 42 to 64 days |
| Description of the vaccine | DTwP-HepB/Hib vaccine. |
| Name of the manufacturer | Crucell Holland BV |
| Name of the manufacturing country | Philippines |
| Year of manufacture | 2011 |
| Clinical Phase status | Clinical - Phase 4 |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Single dose at 6, 10 and 14 weeks. |
| Mechanism of action | Anti-tetanus antibodies. |
| Route of administration | NA |
| Indications | Immunization against diphtheria, tetanus, pertussis (whooping cough), hepatitis B and haemophilus influenzae type b infections. |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | For diphtheria, tetanus, hepatitis B and Haemophilus infections. |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT01357720 |
| Reference | https://www.vaccinebox.com/product/tritanrix-hb-hib/ |
| Other name | NA |
| Additional Links | NA
|